|
SRT1720
N-(2-(3-(1-Piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)-2-quinolinecarboxamide, Sirtuin-3 Inhibitor, SRT1720, SIRT3 Inhibitor II, HAT Inhibitor XI, Histone Acetyltransferase Inhibitor XI, p300/CBP Inhibitor IX
A cell-permeable quinolinecarboxamide compound that is shown to inhibit the mitochondrial SIRT3 in a substrate AceCS2-competitive (Ki = 0.56 µM; Km = 2.44 µM), but NAD+-uncompetitive (Ki = 0.34 µM; Km = 280 µM), manner. Also reported to decrease cellular p53 Lys382 acetylation (Effective conc. = 10 µM in U2OS and MEF cultures) and inhibit p300 HAT activity (IC50 = 9 µM) in vitro, as well as offer therapeutic benefits in several murine and rodent type 2 diabetes models (100 mg/kg/dayl p.o.) in vivo. Whether and how SRT1720 activates SIRT1 activity remains uncertain.
产品信息
Form Yellow solid
Molar mass 469.6
Protect from Light 是的
Packaged under inert gas 是的
Purity ≥97% by HPLC
Solubility DMSO
Chemical formula C25H23N7OS
CAS number 925434-55-5
商店和运输信息
Storage -20°C
Ship Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
Regulatory Review |